Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses

Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses

Metformin has been under basic and clinical study as an oncological repurposing pharmacological agent for several years, stemming from observational studies which consistently evidenced that subjects who were treated with metformin had a reduced risk for development of cancer throughout their lives,...

Full description

Bibliographic Details
Main Authors: Pedro Barrios-Bernal, Zyanya Lucia Zatarain-Barrón, Norma Hernández-Pedro, Mario Orozco-Morales, Alejandra Olivera-Ramírez, Federico Ávila-Moreno, Ana Laura Colín-González, Andrés F. Cardona, Rafael Rosell, Oscar Arrieta
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceuticals
Subjects:
metformin
body mass index
fatty acid oxidation
PHD3
EGFR
Online Access:https://www.mdpi.com/1424-8247/15/7/786

Similar Items

Similar Items